

## Anti-oxLDL Antibody (Orticumab)

### Introduction

Orticumab (MLDL1278A) is a novel biopharmaceutical targeting oxidized or malondialdehyde-modified lipoproteins (LDL). Orticumab specifically inhibits oxidized low-density lipoprotein (oxLDL). Orticumab is involved in regulating the autoimmune response to oxLDL and can improve atherosclerosis in animal models. Orticumab can also be used in studies to improve psoriasis.

### Product parameters

Alternative Names	Anti-oxLDL, RG7418, BI-204
Target Accession	-
Target	oxLDL
CAS number	1314241-10-5
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

